Compartir

Clinical Trials Press Releases

1 de Mayo de 2026

Bipartisan Legislation Aimed at Improving Access to Clinical Trials for Patients Introduced in the Senate

A new bill that would improve access to clinical trials was recently introduced  in the U.S. Senate. Sponsored by Senators Tim Scott (R-S.C.) and Mark Warner (D-Va.), the Clinical Trial Modernization Act (S. 4440) would help reduce cost and geographic barriers, making it easier for patients to take part in clinical trials. U.S. Representatives Raul Ruiz (D-Calif.) and August Pfluger (R-Texas) introduced the House version (H.R. 3521) of this legislation in May 2025.

10 de Febrero de 2026

Rural Populations Face Greater Barriers as Non-Medical Costs Hinder Clinical Trial Access

Today, the American Cancer Society Cancer Action Network (ACS CAN) was joined by 24 other organizations in proposing the Health and Human Services Office of Inspector General adopt a new regulatory safe harbor from the Anti-kickback Statute that would allow clinical trial sponsors to financially support patients to offset indirect or non-medical costs associated with clinical trial participation, such as travel, parking and lodging.

20 de Mayo de 2025

Nueva legislación facilitaría la participación de pacientes en ensayos clínicos

Hoy se presentó en la Cámara de Representantes una nueva legislación federal que facilitaría la participación en estudios clínicos de todos los pacientes con cáncer. Patrocinada por los representantes Raúl Ruiz (demócrata por California) y August Pfluger (republicano por Texas), la Ley de Modernización de Ensayos Clínicos ayudaría a eliminar los obstáculos económicos y geográficos que impiden a los pacientes participar en ensayos clínicos.

11 de Abril de 2018

Report Details Common Patient Barriers to Cancer Clinical Trial Enrollment

The American Cancer Society Cancer Action Network (ACS CAN) today released a report examining the most common patient barriers to cancer clinical trial enrollment. Made public at ACS CAN’s annual national policy forum, the report found only about one in four (27%) patients has access to clinical trials where they are being treated. Yet, if asked to enroll in an available trial, more than half of eligible patients typically agree to do so.